What is MRK's current stock price?

As of now, MRK is trading at $107.40, with a daily change of -0.72%.

What are the risks associated with MRK stock?

MRK has Low, risk level based on volatility, sector strength, volume, investor confidence and outlook.

Market Overview Trending Stocks Stock Screener Trade Insights

Top Rated Stocks Most Active Stocks Top Potential Stocks Top Momentum Stocks Leaderboard

About Us Log In Sign Up Plans & Pricing Contact Us Terms of Use Privacy Policy

Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist

MRK Stock Analysis & IQ Rating | Merck Company

MRK

Merck Company

$107.40

-$0.78 | -0.72%

Set Alerts

Overview

Comments

Insights

Risks

Rating

Chart

Analysts

Street

Sentiment

Headlines

52W High

$112.9

MKT CAP

$266.57B

52W Low

$73.31

VOL

$6.86M

P/E Ratio

14.2

AVG VOL

$13.55M

RSI

52.34

TREND

Uptrend

MRK Stock IQ

Login to see Merck Company (MRK) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid

MRK Target Price

Login to display

Strengths

MRK Rewards

Earnings are forecast to grow

MRK Rewards

Upgraded on attractively valued

MRK Rewards

Outperform the market

MRK Rewards

Trading below its fair value

Risk Analysis

MRK Risk Analysis

Investors losing their confidence

MRK Price Performance

$106.78 (+0.58%)

$86.58 (+24.05%)

$85.48 (+25.64%)

$86.4 (+24.31%)

1year

6month

3month

1month

MRK Analysts Opinion

Overall standing based on market and analyst consensus. menu Hover over the category for more information

MRK Analysts Opinion

MRK Analysts opinion is positive and also has improved from the past 3 months

MRK Street Sentiment

Analysts perspectives on the stock desirability, trend direction and growth potential

77%

Buy
Opinion

Trend
Score

Potential
Score

Consensus Rating

100%

60%

87%

MRK Street Sentiment

MRK Street Sentiment is extremely bullish and have positive views on the near-term outlook

MRK Risk Level

MRK has Low risk level

Low

LOW

HIGH

MRK Performance Sentiment

Sentiments overview associated with events and the stock performance

77%

15%

Positive

Negative

51 out of 66
events present

10 out of 66
events present

Very Bullish

Bullish

Neutral

Bearish

Very Bearish

Technical Price Levels

Average key support and resistance price levels

Support
Price

$108.18

Resistance
Price

$100.10

Current Price Range

$111.11

Show methods +

Linked to MRK

IQ

Close Price

Change

AZN

4.60

94.23

+1.38%

PFE

4.67

25.88

+0.90%

NVS

4.33

149.12

+1.35%

SNY

2.93

47.33

+0.28%

ABBV

3.73

220.77

+0.69%

Recently Viewed

Close Price

Change

MRK

Merck Company

107.40

-0.72%

MREO

Mereo BioPharma Group

0.49

-6.64%

SOFI

SoFi Technologies In

25.80

-0.19%

RZLV

Rezolve AI PLC

2.84

-9.55%

XXII

22nd Century

11.31

+7.65%

MRK Latest Analysis +

Moderna (MRNA) Stock Pulls Back After Recent Strength. MRNA) shares are down on Monday pulling back after recent updates highlighting its latest cancer trial results. Here’.s what investors .Moderna stock is trending lower. The recent downturn follows Moderna’.s announcement that its melanoma vaccine mRNA-4157 showed promising results in a Phase 2b study reducing the risk of recurrence or death by 49% when combined with ) Keytruda.In addition to the trial data Moderna has multiple ongo

Mon Jan 26, 2026

$107.40 | -0.72%

Activity

Revolution Medicines Stock Sinks After Merck Deal Talks Collapse. ) has reportedly ended discussions to acquire cancer drug developer RVMD) after the two sides disagreed on valuation.Earlier in January the Financial Times reported that Merck is reportedly in talks to acquire Revolution Medicinesin a deal potentially valued at .The talks had valued Revolution Medicines at roughly $30 billion. Citing people familiar with the matter the Wall Street Journal report on Sunday Merck’.s continued

Mon Jan 26, 2026

$107.40 | -0.72%

Activity

Momentum

Potential

Wall Street Has a Positive Opinion on Guardant Health (GH). Guardant Health Inc. (NASDAQ:GH) is one of the Best Russell 2000 Stocks to Buy Right Now. Wall Street has a positive opinion on Guardant Health Inc. (NASDAQ:GH). Recently on January 19 Guardant Health Inc. (NASDAQ:GH) announced a multi-year partnership with Merck. The collaboration aims to support Mercks oncology drug development and sales efforts through Guardants [….]

Fri Jan 23, 2026

$108.18 | -0.91%

Activity

Potential

Why Moderna Stock Surged Today. Key PointsModernas and Mercks partnership could help to advance cancer care.

Thu Jan 22, 2026

$109.18 | -1.74%

Activity

Broader Analyst Sentiment ish on Merck & Co. (MRK) Amid Tempered Short-Term Expectation and Long-Term Optimism.

Wed Jan 21, 2026

$111.11 | +1.49%

Potential

Moderna–Merck Cancer Vaccine Shows Durable Benefit At 5 Years In High-Risk Melanoma. MRNA) and ) on Tuesday shared median from the Phase 2b KEYNOTE-942/mRNA-4157-P201 study of mRNA-based individualized neoantigen therapy for a serious type of skin cancer.The trial evaluated intismeran autogene (mRNA-4157 or V940) in combination with Merck’.s Keytruda (pembrolizumab) for (stage III/IV) following complete resection (removed surgically).In this pre-planned analysis adjuvant treatment with in

Tue Jan 20, 2026

$109.45 | +0.57%

Potential

Will Weak Gardasil Sales Continue to Ail MRK Revenues in Q4 Earnings?. Gardasils sharp sales slump in China and Japan puts Merck under pressure heading into Q4 earnings with the vaccines sales expected to stay under strain.

Tue Jan 20, 2026

$109.45 | +0.57%

Activity

Momentum

Potential

Merck (MRK) Builds Post-Keytruda Growth Plan BMO Upgrades to Outperform. Merck &. Co. Inc. (NYSE:MRK) ranks among the most active blue chip stocks to buy now. With a raised price target of $130 per share BMO Capital Markets upgraded Merck &. Co. Inc. (NYSE:MRK) to Outperform on December 18 stating that the pharmaceutical company is working on a portfolio that can continue growth beyond the [….]

Tue Jan 20, 2026

$109.45 | +0.57%

Potential

Rating

Arbutus Biopharma Shares Fall 19% On European Patent Revocation . (RTTNews) - Arbutus Biopharma Corp. (ABUS) saw its stock tumble after the European Patent Office (EPO) revoked one of its key lipid nanoparticle (LNP) patents EP2279254 after years of opposition proceedings initiated by Moderna and Merck affiliates.

Fri Jan 16, 2026

$108.83 | -1.93%

Momentum

Merck KGaA (MKKGY) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow.

Thu Jan 15, 2026

$110.95 | -0.06%

Activity

FAQ About MRK Stock Insights

What is MRK current stock price?

What are MRK stock strengths?

What is MRK Risk Level?

What is MRK market cap and volume?

What is MRK current Stock IQ?

Should I buy MRK stock right now?

Is MRK a Strong Buy right now?

What does a 'Strong Buy' rating mean for MRK?

What does a 'Strong Sell' rating mean for MRK?

What factors influence MRK's Stock IQ?

Explore our MRK Stock insights

In-Depth Market Analysis and Trends
Expert Insights on Market Dynamics
Tailored MRK Stock Strategies
Effective Risk Management

FIND US ON

Receive our MRK Daily Alerts

Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts

Market Trends

Stay ahead of the market

Market trends

Investment tips

Market analysis service

Investment Insights

Future potential

Informed investment decisions

Investment analysis

IInvestment strategies

Stock Analysis

In-depth stock analysis

Performance analysis

Stock market insights

Financial trends analysis

MRK

Merck Company

Set Alerts

Current Price

$107.40

-$0.78 | -0.72%

52W High

$112.9

MKT CAP

$266.57B

52W Low

$73.31

VOL

$6.86M

P/E Ratio

14.2

AVG VOL

$13.55M

RSI

52.34

TREND

Uptrend

Overview

Comments

Insights

Risks

Rating

Chart

Analysts

Street

Sentiment

Target Price

Login to display

Stock Insights

Strengths

MRK Rewards

Earnings are forecast to grow

MRK Rewards

Upgraded on attractively valued

MRK Rewards

Outperform the market

MRK Rewards

Trading below its fair value

Risk Analysis

MRK Risk Analysis

Investors losing their confidence

Linked to MRK

Symbol

IQ

Close

Change

AZN

4.60

94.23

+1.38%

PFE

4.67

25.88

+0.90%

NVS

4.33

149.12

+1.35%

SNY

2.93

47.33

+0.28%

ABBV

3.73

220.77

+0.69%

MRK Street Sentiment

Analysts perspectives on the stock desirability, trend direction and growth potential

77%

Buy
Opinion

Trend
Score

Potential
Score

Consensus Rating

100%

60%

87%

MRK Street Sentiment

MRK Street Sentiment is extremely bullish and have positive views on the near-term outlook

MRK Risk Level

MRK has Low risk level

Low

LOW

HIGH

MRK Performance Sentiment

Sentiments overview associated with events and the stock performance.

77%

15%

Positive

Negative

51 out of 66
events present

10 out of 66
events present

Very Bullish

Bullish

Neutral

Bearish

Very Bearish

Technical Price Levels

Average key support and resistance price levels

Support
Price

$108.18

Resistance
Price

$100.10

Current Price Range

$111.11

Show methods +

Latest Analyst Actions

Overall Wall Street Rating

75%

Buy

Hold

Sell

Consensus Rating

BUY

6

2

0

Date

Action

Rating

Firm

Jan 20, 2026

Upgrade

Buy

BMO Capital

Jan 09, 2026

Upgrade

Outperform

Wolfe Research

Jan 08, 2026

Upgrade

Outperform

Wolfe Research

Dec 19, 2025

Upgrade

Outperform

BMO Capital

Dec 18, 2025

Price Target Raised

Outperform

BMO Capital

MRK Stock IQ

Login to unlock Merck Company (MRK) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid

MRK Latest Analysis

Moderna (MRNA) Stock Pulls Back After Recent Strength. MRNA) shares are down on Monday pulling back after recent updates highlighting its latest cancer trial results. Here’.s what investors .Moderna stock is trending lower. The recent downturn follows Moderna’.s announcement that its melanoma vaccine mRNA-4157 showed promising results in a Phase 2b study reducing the risk of recurrence or death by 49% when combined with ) Keytruda.In addition to the trial data Moderna has multiple ongo

Mon Jan 26, 2026

$107.40 | -0.72%

Activity

Revolution Medicines Stock Sinks After Merck Deal Talks Collapse. ) has reportedly ended discussions to acquire cancer drug developer RVMD) after the two sides disagreed on valuation.Earlier in January the Financial Times reported that Merck is reportedly in talks to acquire Revolution Medicinesin a deal potentially valued at .The talks had valued Revolution Medicines at roughly $30 billion. Citing people familiar with the matter the Wall Street Journal report on Sunday Merck’.s continued

Mon Jan 26, 2026

$107.40 | -0.72%

Activity

Momentum

Potential

Wall Street Has a Positive Opinion on Guardant Health (GH). Guardant Health Inc. (NASDAQ:GH) is one of the Best Russell 2000 Stocks to Buy Right Now. Wall Street has a positive opinion on Guardant Health Inc. (NASDAQ:GH). Recently on January 19 Guardant Health Inc. (NASDAQ:GH) announced a multi-year partnership with Merck. The collaboration aims to support Mercks oncology drug development and sales efforts through Guardants [….]

Fri Jan 23, 2026

$108.18 | -0.91%

Activity

Potential

Why Moderna Stock Surged Today. Key PointsModernas and Mercks partnership could help to advance cancer care.

Thu Jan 22, 2026

$109.18 | -1.74%

Activity

Broader Analyst Sentiment ish on Merck & Co. (MRK) Amid Tempered Short-Term Expectation and Long-Term Optimism.

Wed Jan 21, 2026

$111.11 | +1.49%

Potential

Moderna–Merck Cancer Vaccine Shows Durable Benefit At 5 Years In High-Risk Melanoma. MRNA) and ) on Tuesday shared median from the Phase 2b KEYNOTE-942/mRNA-4157-P201 study of mRNA-based individualized neoantigen therapy for a serious type of skin cancer.The trial evaluated intismeran autogene (mRNA-4157 or V940) in combination with Merck’.s Keytruda (pembrolizumab) for (stage III/IV) following complete resection (removed surgically).In this pre-planned analysis adjuvant treatment with in

Tue Jan 20, 2026

$109.45 | +0.57%

Potential

Will Weak Gardasil Sales Continue to Ail MRK Revenues in Q4 Earnings?. Gardasils sharp sales slump in China and Japan puts Merck under pressure heading into Q4 earnings with the vaccines sales expected to stay under strain.

Tue Jan 20, 2026

$109.45 | +0.57%

Activity

Momentum

Potential

Merck (MRK) Builds Post-Keytruda Growth Plan BMO Upgrades to Outperform. Merck &. Co. Inc. (NYSE:MRK) ranks among the most active blue chip stocks to buy now. With a raised price target of $130 per share BMO Capital Markets upgraded Merck &. Co. Inc. (NYSE:MRK) to Outperform on December 18 stating that the pharmaceutical company is working on a portfolio that can continue growth beyond the [….]

Tue Jan 20, 2026

$109.45 | +0.57%

Potential

Rating

Arbutus Biopharma Shares Fall 19% On European Patent Revocation . (RTTNews) - Arbutus Biopharma Corp. (ABUS) saw its stock tumble after the European Patent Office (EPO) revoked one of its key lipid nanoparticle (LNP) patents EP2279254 after years of opposition proceedings initiated by Moderna and Merck affiliates.

Fri Jan 16, 2026

$108.83 | -1.93%

Momentum

Merck KGaA (MKKGY) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow.

Thu Jan 15, 2026

$110.95 | -0.06%

Activity

Discover MRK Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends and the future potential of MRK. We're here to help you make informed investment decisions today.

FIND US ON

Receive our MRK Daily Alerts

Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts

Market trends

In-depth stock analysis

Informed investment decisions

Stock market insights

Stock trading tips

Stock analysis

MRK Stock trends

MRK Stock performance

MRK Stock analysis

MRK investment strategies

Stock strategies

Trading strategies

StocksRunner updates

StocksRunner Insights

Financial Reports

Disclaimer: Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor. The Readiness Indicators, Sentiment Indicators and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses. Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

✕

Don't Be a Sheep, Be a StocksRunner

StocksRunner Aggregates The Most Important Headlines Into A Single Stock IQ

Sign up for free and

continue analysing MRK

Signup to Stocksrunner

Already a Member? Click here to Login

Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence and cutting-edge intelligence.

✕

Don't Be a Sheep, Be a StocksRunner

StocksRunner Aggregates The Most Important Headlines Into A Single Stock IQ

Sign up for free and

continue analysing MRK

Signup to Stocksrunner

Already a Member? Click here to Login

Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence and cutting-edge intelligence.

MRK Stock Analysis & IQ Rating | Merck Company

MRK Stock IQ

MRK Target Price

MRK Analysts Opinion

MRK Street Sentiment

MRK Risk Level

MRK Performance Sentiment

Technical Price Levels

Explore our MRK Stock insights

Receive our MRK Daily Alerts

MRK Street Sentiment

MRK Risk Level

Technical Price Levels

Latest Analyst Actions

Discover MRK Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends and the future potential of MRK. We're here to help you make informed investment decisions today.

Receive our MRK Daily Alerts

MRK Alerts